<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="The Journal of Experimental Medicine"><meta name="citation_title" content="A Peptide-binding Motif for I-Ag7, the Class II Major  Histocompatibility Complex (MHC) Molecule of NOD and Biozzi AB/H Mice"><meta name="citation_authors" content="Leonard C. Harrison, Margo C. Honeyman, Sylvie Trembleau, Silvia Gregori, Fabio Gallazzi, Petra Augstein, Vladimir Brusic, Juergen Hammer, and  Luciano Adorini"><meta name="citation_date" content="1997 March 17"><meta name="citation_issue" content="6"><meta name="citation_volume" content="185"><meta name="citation_firstpage" content="1013"><meta name="citation_pdf_url" content="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2196246&amp;blobtype=pdf"><meta name="citation_abstract_html_url" content="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2196246&amp;rendertype=abstract"><meta name="citation_fulltext_html_url" content="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2196246"><meta name="citation_pmid" content="9091575"><meta name="DC.Title" content="A Peptide-binding Motif for I-Ag7, the Class II Major  Histocompatibility Complex (MHC) Molecule of NOD and Biozzi AB/H Mice"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="The Rockefeller University Press"><meta name="DC.Contributor" content="Leonard C. Harrison"><meta name="DC.Contributor" content="Margo C. Honeyman"><meta name="DC.Contributor" content="Sylvie Trembleau"><meta name="DC.Contributor" content="Silvia Gregori"><meta name="DC.Contributor" content="Fabio Gallazzi"><meta name="DC.Contributor" content="Petra Augstein"><meta name="DC.Contributor" content="Vladimir Brusic"><meta name="DC.Contributor" content="Juergen Hammer"><meta name="DC.Contributor" content="Luciano Adorini"><meta name="DC.Date" content="1997 March 17"><meta name="DC.Language" content="en"><link rel="stylesheet" href="corehtml/pmc/css/pmcstatic.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbase1.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbars-gray.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbody7.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcrefs1.css" type="text/css"><script type="text/javascript" src="corehtml/pmc/js/common.js"></script><script type="text/javascript">window.name="mainwindow";</script><link href="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/css/tileshop_pmc.1/tileshop_pmc.1.css" type="text/css" rel="stylesheet"><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/utils.1.js"></script><script>utils.jsLoader.sBase = "http://www.ncbi.nlm.nih.gov/corehtml/jsutils/";</script><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/tileshop_pmc.1/tileshop_pmc.1.js"></script><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corecgi/tileshop/tileshop_data_db.1.js"></script><title>A Peptide-binding Motif for I-Ag7, the Class II Major  Histocompatibility Complex (MHC) Molecule of NOD and Biozzi AB/H Mice</title></head><body class="pmc-body"><a id="top" name="top"></a><table cellpadding="0" cellspacing="0" width="100%" border="0"><tr valign="top"><td colspan="3"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse;"><tr><td width="145" valign="top"><img src="corehtml/pmc/pmcgifs/pmc3_logo_v5.gif" border="0" usemap="#pmclogo" alt="pmc logo image"><map name="pmclogo"><area shape="rect" alt="Journal List" coords="65,52,137,67" href="fprender.fcgi"><area shape="rect" alt="Search" coords="7,52,52,67" href="redirect3.cgi?&amp;&amp;auth=02OfczvtYYGpT3vzaTpOl24OqjL2QXpapfzXxTQt5&amp;reftype=other&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CLogo&amp;TO=Entrez%7CSearch%7CAll%20PMC&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc"><area shape="rect" alt="pmc logo image" coords="0,0,145,75" href="./"></map></td><td height="75" valign="top" style="padding-left: 4px;"><div><img align="top" border="0" src="corehtml/pmc/pmcgifs/logo-jexpmed-article.gif" alt="Logo of jexpmed" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" alt="This Article at jem.org" coords="203,55,328,85" href="redirect3.cgi?&amp;&amp;auth=0dwmwEjoqI67gn11PKS_LqMNkpKTjKRtDA6eK9AAL&amp;reftype=publisher&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CBanner&amp;TO=Publisher%7CArticle%7CFullText&amp;rendering-type=normal&amp;&amp;http://www.jem.org/cgi/content/full/185/6/1013" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="The Journal of Experimental Medicine" coords="0,0,188,73" href="redirect3.cgi?&amp;&amp;auth=0jyjSyV0mpCRfcxEDWoUcmRa7U9QNwk4seLDseQ8B&amp;reftype=publisher&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://www.jem.org" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="Editors" coords="378,56,425,76" href="redirect3.cgi?&amp;&amp;auth=0LQF4cwsfDzNsICGe1yoLMp2FJzahO1zyKmFBQQVj&amp;reftype=publisher&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://www.jem.org/misc/edboard.shtml" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="Contact" coords="482,55,535,77" href="redirect3.cgi?&amp;&amp;auth=0FOH2THc7SM7YNsyvlPBOX0otythH2XqFXmGaTQNF&amp;reftype=publisher&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://www.jem.org/misc/contacts.shtml" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="Instructions to Authors" coords="592,57,692,95" href="redirect3.cgi?&amp;&amp;auth=0JWY2YGrrR3rEae6nu7qo7sexXY6E9MXMVZaWE5jP&amp;reftype=publisher&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://www.jem.org/misc/ifora.shtml" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="The Rockefeller University Press" coords="532,-3,696,53" href="redirect3.cgi?&amp;&amp;auth=0PaKWRtGdNIjx8SYwSBXn6ZlxxYZQYD9In_3MTAgX&amp;reftype=publisher&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://www.rupress.org" target="pmc_ext" onclick="focuswin('pmc_ext')"></map></div></td></tr></table></td></tr></table><table cellpadding="0" cellspacing="3" width="100%" border="0"><tr><td></td><td colspan="2"><div class="navlink-box navlink-box-gray"><a href="fprender.fcgi" class="navlink">Journal List</a><span> &gt; </span><a class="navlink" href="tocrender.fcgi?journal=483&amp;action=archive">J Exp Med</a><span> &gt; </span><a class="navlink" href="tocrender.fcgi?iid=158993">v.185(6); Mar 17, 1997</a></div></td></tr><tr><td width="145" valign="top" class="sidebar-cell"><div class="sidebar-article-navigation-box"><div class="sidefm-pmclink-item"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=abstract" class="sidefm-pmclink">Abstract</a></div><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Full Text</a></div><div class="sidefm-pmclink-item"><a href="picrender.fcgi?artid=2196246&amp;blobtype=pdf" class="sidefm-pmclink">PDF (147K)</a></div><div class="sidefm-pmclink-item"><a href="tocrender.fcgi?iid=158993" class="sidefm-pmclink">Contents</a></div><div class="sidefm-pmclink-item"><a href="tocrender.fcgi?journal=483&amp;action=archive" class="sidefm-pmclink">Archive</a></div></div><div class="sidebar-pubmed-box"><div class="sidebar-pubmed-links-to-box"><form name="pubmedLinks" onsubmit="return pubMedDbLinkSubmit(this)"><div class="sidefm-pmsubhead"><label for="pubmedOption">Related material:</label></div><select name="pubmedOption" id="pubmedOption" class="sidefm-pmart" onchange="return pubMedDbLinkSubmit(this)"><option value="redirect3.cgi?&amp;&amp;auth=045ERx94OHHWijK-ngjahaTu_1o5jQ8L9gC3c8QwN&amp;reftype=abs&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9091575">PubMed record</option><option selected value="redirect3.cgi?&amp;&amp;auth=0pAaX0r8KqC9WEvCrvAA2e_g21_f0cabI3WoNUkdo&amp;reftype=relart&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Related%20Records&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Link&amp;dbFrom=PubMed&amp;from_uid=9091575">PubMed related arts</option><option value="redirect3.cgi?&amp;&amp;auth=0J9jV4J8uNSSF0UWBzAIe2pBrp9Omx32ZXikXPA1Q&amp;reftype=linkout&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Linkout&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowLinkOut&amp;TermToSearch=9091575">PubMed LinkOut</option><option value="redirect3.cgi?&amp;&amp;auth=0ZaGLqKNgQH3D4ZotIxRRGTKtxOE25RqL-a7nDAIA&amp;reftype=Substance&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc&amp;cmd=Display&amp;from_uid=2196246&amp;dopt=pmc_pcsubstance">Substance</option><option value="redirect3.cgi?&amp;&amp;auth=0FENgP3MTss5DhdFX3ywouRwU_fGxaJgtBfm7YQQA&amp;reftype=Taxonomy&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc&amp;cmd=Display&amp;from_uid=2196246&amp;dopt=pmc_taxonomy">Taxonomy</option><option value="redirect3.cgi?&amp;&amp;auth=0lakXhQwqwMNOl0y5Helq5QlyXPZu2ucka-NLAQq9&amp;reftype=Taxonomy&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?Db=taxonomy&amp;DbFrom=pmc&amp;cmd=Link&amp;LinkName=pmc_taxonomy&amp;doptcmdl=TxTree&amp;IdsFromResult=2196246">Taxonomy tree</option></select><br><input type="image" src="corehtml/pmc/pmcgifs/go.gif" alt="Go" class="sidefm-pmart"></form></div><div class="sidebar-pubmed-author-box"><div class="sidefm-pmsubhead">PubMed articles by:</div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0hSLJLrC5vKq6yeq3NO8-NZprQsE7LkU2ja1SJ5BF&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Harrison+LC%5Bauth%5D" class="sidefm-pmclink"> Harrison, L.</a></div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=02aqFG8G5rimLYeI4HHRLQT-0YZqtcUYIJnpBfQ6J&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Honeyman+MC%5Bauth%5D" class="sidefm-pmclink"> Honeyman, M.</a></div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0FkxbO6mLProMeIg2dUabUYuY93CIxAhNIT73G5V_&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Trembleau+S%5Bauth%5D" class="sidefm-pmclink"> Trembleau, S.</a></div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0Bo99q7CP3uKtyJXUvFUG90vYiQzOF_35rMSNyQIg&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Adorini+L%5Bauth%5D" class="sidefm-pmclink"> Adorini, L.</a></div></div></div></td><td rowspan="102" width="20px" height="300" background="corehtml/pmc/pmcgifs/wm-jexpmed.gif"><div style="width:20px"></div></td><td valign="top" class="content-cell"><div class="front-matter-section"><table cellspacing="0" cellpadding="0" width="100%"><tr style="vertical-align: top"><td><div class="fm-citation"><div><span class="citation-abbreviation">J Exp Med. </span><span class="citation-publication-date">1997 March 17; </span><span class="citation-volume">185</span><span class="citation-issue">(6)</span><span class="citation-flpages">: 1013–1022. </span></div><div><span class="fm-vol-iss-date"> </span></div></div></td><td class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span>PMC2196246</div></td></tr></table><div class="fm-copyright"><a class="int-reflink" href="about/copyright.html">Copyright notice</a> </div><div class="fm-doctopic">Articles</div><div class="fm-title">A Peptide-binding Motif for I-A<sup>g7</sup>, the Class II Major  Histocompatibility Complex (MHC) Molecule of NOD and Biozzi AB/H Mice</div><div class="fm-author contrib-group">Leonard C. Harrison,<sup>&#x0002a;</sup> Margo C. Honeyman,<sup>&#x0002a;</sup> Sylvie Trembleau,<sup>&#x02021;</sup> Silvia Gregori,<sup>&#x02021;</sup> Fabio Gallazzi,<sup>&#x02021;</sup> Petra Augstein,<sup>&#x0002a;</sup> Vladimir Brusic,<sup>&#x0002a;</sup> Juergen Hammer,<sup>&#x02021;</sup> and  Luciano Adorini<sup>&#x02021;</sup><div class="fm-affl">From <sup>&#x0002a;</sup>the Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville  3050, Australia; and <sup>&#x02021;</sup>Roche Milano Ricerche, 1-20132, Milano, Italy</div></div><div class="fm-footnote"></div><div class="fm-footnote"><div class="p">Address correspondence to L.C. Harrison, The Walter and Eliza Hall Institute of Medical Research, Post  Office, Royal Melbourne Hospital, Parkville, 3050, Australia.</div></div><div class="fm-pubdate">Received November 18, 1996; Revised January 8, 1997.</div><div class="links-box"><div class="fm-footnote"><img src="corehtml/pmc/pmcgifs/rt-arrow.gif" alt="Small right arrow pointing to:" style="vertical-align: middle;"> This article has been <a class="int-reflink" href="tocrender.fcgi?artid=2196246&amp;action=cited">cited by</a> other articles in PMC.</div></div></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Abstract</a></div><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id343666" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id343937" class="sidefm-pmclink" style="text-transform: none;">Results and Discussion</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id353316" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id154430">Abstract</div><div class="section-content"><!--article-meta-->The class II major histocompatibility complex molecule I-A<sup>g7</sup> is strongly linked to the development of spontaneous insulin-dependent diabetes mellitus (IDDM) in non obese diabetic mice  and to the induction of experimental allergic encephalomyelitis in Biozzi AB/H mice. Structurally,  it resembles the HLA-DQ molecules associated with human IDDM, in having a non-Asp residue at position 57 in its &#x003b2; chain. To identify the requirements for peptide binding to I-A<sup>g7</sup> and  thereby potentially pathogenic T cell epitopes, we analyzed a known I-A<sup>g7</sup>-restricted T cell  epitope, hen egg white lysozyme (HEL) amino acids 9&#x02013;27. NH<sub>2</sub>- and COOH-terminal truncations demonstrated that the minimal epitope for activation of the T cell hybridoma 2D12.1  was M12-R21 and the minimum sequence for direct binding to purified I-A<sup>g7</sup> M12-Y20/ K13-R21. Alanine (A) scanning revealed two primary anchors for binding at relative positions  (p) 6 (L) and 9 (Y) in the HEL epitope. The critical role of both anchors was demonstrated by  incorporating L and Y in poly(A) backbones at the same relative positions as in the HEL  epitope. Well-tolerated, weakly tolerated, and nontolerated residues were identified by analyzing the binding of peptides containing multiple substitutions at individual positions. Optimally,  p6 was a large, hydrophobic residue (L, I, V, M), whereas p9 was aromatic and hydrophobic (Y  or F) or positively charged (K, R). Specific residues were not tolerated at these and some other  positions. A motif for binding to I-A<sup>g7</sup> deduced from analysis of the model HEL epitope was  present in 27/30 (90%) of peptides reported to be I-A<sup>g7</sup>&#x02013;restricted T cell epitopes or eluted  from I-A<sup>g7</sup>. Scanning a set of overlapping peptides encompassing human proinsulin revealed  the motif in 6/6 good binders (sensitivity &#x0003d; 100%) and 4/13 weak or non-binders (specificity &#x0003d;  70%). This motif should facilitate identification of autoantigenic epitopes relevant to the pathogenesis and immunotherapy of IDDM.</div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id154430" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id343666" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id343937" class="sidefm-pmclink" style="text-transform: none;">Results and Discussion</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id353316" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id154202"> </div><div class="section-content">Non obese diabetic (NOD)<sup>1</sup> mice develop autoimmune, T cell&#x02013;mediated destruction of pancreatic islet  &#x003b2; cells and are a model of human insulin-dependent diabetes mellitus (IDDM) (<a href="#B1" class="cite-reflink bibr">1</a>). In common with humans who  develop IDDM, NOD mice have immune responses to islet autoantigens such as insulin and glutamic acid decarboxylase (GAD). In addition, they share a structurally similar  class II MHC molecule associated with disease susceptibility. This molecule, I-A<sup>g7</sup>, has a &#x003b2; chain sequence otherwise  found only in Biozzi AB/H mice that are susceptible to  chronic relapsing experimental allergic encephalomyelitis  (CR-EAE) (<a href="#B2" class="cite-reflink bibr">2</a>). It is characterized by a non-Asp residue at  position 57 (<a href="#B3" class="cite-reflink bibr">3</a>), as in the &#x003b2; chain of the HLA-DQ molecules associated with human IDDM (<a href="#B4" class="cite-reflink bibr">4</a>). The capacity of  these unique class II molecules to bind and present peptides  to autoreactive T cells could be critical in the development  of IDDM and CR-EAE.<p>Although amino acid motifs for peptides that bind to individual class I and some class II MHC molecules have been  well defined (<a href="#B5" class="cite-reflink bibr">5</a>, <a href="#B6" class="cite-reflink bibr">6</a>), the rules that govern binding of peptides to I-A<sup>g7</sup> are still unclear. Reich et al. (<a href="#B7" class="cite-reflink bibr">7</a>) eluted and sequenced several naturally processed peptides from I-A<sup>g7</sup>  and concluded that binding may require an acidic residue  in the COOH terminus of the peptide. Carrasco-Marin et  al. (<a href="#B8" class="cite-reflink bibr">8</a>) found that I-A<sup>g7</sup> either on the surface of antigen-presenting cells or in SDS-PAGE after its purification was unstable and that the binding of known I-A<sup>g7</sup>&#x02013;restricted T cell  epitopes or the peptides eluted by Reich et al. (<a href="#B7" class="cite-reflink bibr">7</a>) was difficult or impossible to demonstrate. This led them to hypothesize that weak peptide binding by I-A<sup>g7</sup> militated against  elimination of autoreactive T cells in the NOD mouse.  Amor et al. (<a href="#B9" class="cite-reflink bibr">9</a>) investigated the fine specificity of peptides  from myelin oligodendrocyte glycoprotein (MOG) or proteolipid protein (PLP) for the induction of experimental allergic encephalomyelitis (EAE) in Biozzi AB/H mice and  suggested a core motif for I-A<sup>g7</sup> binding peptides.</p><p>In this study, we used the I-A<sup>g7</sup>&#x02013;restricted T cell epitope,  hen egg white lysozyme (HEL) amino acids 9&#x02013;27, as a template with which to analyze the amino acid sequence of  peptides that bind to purified, native I-A<sup>g7</sup> and activate a T  cell hybridoma. This has enabled us to define general rules  that identify most known I-A<sup>g7</sup> binding peptides.</p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id154430" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Materials and Methods</a></div><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id343937" class="sidefm-pmclink" style="text-transform: none;">Results and Discussion</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id353316" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id343666">Materials and Methods</div><div class="section-content"><p><span class="head3">Purification of I-A<sup>g7</sup>. </span> I-A<sup>g7</sup> protein was affinity-purified from  detergent lysates of 4G4.7 B cell hybridoma cells by desorption  from OX-6 mouse monoclonal antibody. The 4G4.7 B cell hybridoma was derived by polyethylene glycol (PEG)-induced fusion of  NOD mouse T cell&#x02013;depleted splenocytes with the HAT-sensitive  A20.2J lymphoma line (<a href="#B10" class="cite-reflink bibr">10</a>). OX-6 is a mouse monoclonal IgG1  antibody against an invariant determinant of rat Ia, which also recognizes I-A<sup>g7</sup> but not I-A<sup>d</sup> (<a href="#B11" class="cite-reflink bibr">11</a>, <a href="#B12" class="cite-reflink bibr">12</a>). Approximately 15 mg of OX-6 antibody was first bound to 4 ml of protein A&#x02013;Sepharose 4 Fastflow  (<span style="font-style: italic">Pharmacia</span>, Uppsala, Sweden) and then chemically cross-linked to  the protein A with dimethyl pimelimidate dihydrochloride (<span style="font-style: italic">Sigma  Chemical Co.</span>, St. Louis, MO) in sodium borate buffer, pH 9.0. After 60 min at room temperature (RT), the reaction was quenched  by incubating the Sepharose in 0.2 M ethanolamine, pH 8.0, for  60 min at RT. The suspension was washed thoroughly in PBS  and stored in PBS, 0.02% sodium azide (NaN<sub>3</sub>).<p>4G4.7 cells were harvested by centrifugation, washed in PBS,  resuspended at 10<sup>8</sup> cells/ml of lysis buffer, and then allowed to  stand at 4&#x000b0;C for 120 min. The lysis buffer was 0.05 M sodium  phosphate, pH 7.5, containing 0.15 M NaCl, 1% (vol/vol) NP40 detergent and the following protease inhibitors: 1 mM phenylmethylsulphonyl fluoride, 5 mM &#x003b5;-amino-<em>n</em>-caproic acid and  10 &#x003bc;g/ml each of soybean trypsin inhibitor, antipain, pepstatin,  leupeptin and chymotrypsin. Lysates were cleared of nuclei and  debris by centrifugation at 27,000 <em>g</em> for 30 min and stored as such  if not immediately processed further. To the postnuclear supernatant was added 0.2 vol of 5% sodium deoxycholate (DOC). After  mixing at 4&#x000b0;C for 10 min, the supernatant was centrifuged at  100,000 <em>g</em> at 4&#x000b0;C for 120 min, carefully decanted, and filtered  through a 0.45-&#x003bc;m nylon membrane. The lysate of 5 &#x000d7; 10<sup>10</sup>  4G4.7 cells was gently mixed overnight at 4&#x000b0;C with 4 ml of OX6&#x02013;protein A&#x02013;Sepharose, and the suspension then poured into a  column and washed with at least 50 vol each of buffers A, B, and  C. Buffer A was 0.05 M Tris, pH 8.0, 0.15 M NaCl, 0.5% NP40, 0.5% DOC, 10% glycerol, and 0.03% NaN<sub>3</sub>; buffer B was  0.05 M Tris, pH 9.0, 0.5 M NaCl, 0.5% NP-40, 0.5% DOC,  10% glycerol, and 0.03% NaN<sub>3</sub>; buffer C was 2 mM Tris, pH 8.0,  1% octyl-&#x003b2;-<span class="small-caps">d</span>-glucopyranoside (OGP), 10% glycerol, and 0.03%  NaN<sub>3</sub>. Bound I-A<sup>g7</sup> was eluted with 50 mM diethylamine HCl,  pH 11.5 in 0.15 M NaCl, 1 mM EDTA, 1% OGP, 10% glycerol,  and 0.03% NaN<sub>3</sub>, and immediately neutralized with 1 M Tris.</p></p><p><span class="head3">Peptide Synthesis. </span> Peptides were synthesized with a multiple  peptide synthesizer (model 396; Advanced ChemTech, Louisville, KY) using Fmoc chemistry and solid phase synthesis on  Rink Amide resin. All acylation reactions were effected with a  threefold excess of activated Fmoc amino acids, and a standard  coupling time of 20 min was used. Each Fmoc amino acid was  coupled at least twice. Cleavage and side chain deprotection was  achieved by treating the resin with 90% trifluoroacetic acid, 5%  thioanisole, 2.5% phenol, 2.5% water. The indicator peptide for  the binding assay was biotinylated before being cleaved from resin  by coupling two 6-aminocaproic acid spacers on the NH<sub>2</sub> terminus and one biotin molecule sequentially, using the above-described  procedure. Individual peptides were analyzed by reverse-phase  HPLC and those used in this study were routinely <img src="corehtml/pmc/pmcents/ges.gif" border="0" alt="[gt-or-equal, slanted]" />85% pure.</p><p><span class="head3">T Cell Hybridoma. </span> Hybridoma 2D12.1 was generated by PEG- induced fusion of HEL-immune lymph node cells from a NOD  mouse with the TCR-&#x003b1;/&#x003b2;&#x02013;negative variant of the BW5147 thymoma, as described previously (<a href="#B13" class="cite-reflink bibr">13</a>). Reactivity of 2D12.1 to HEL  peptides was assayed by incubating 2.5 &#x000d7; 10<sup>5</sup> NOD spleen cells  and HEL peptides (0.3 nM to 10 &#x003bc;m) with 5 &#x000d7; 10<sup>4</sup> T hybridoma  cells/well. Culture medium was RPMI 1640 supplemented with  10% FCS, 2 mM <span class="small-caps">l</span>-glutamine, 50 &#x003bc;g/ml gentamicin, and 50  &#x003bc;m 2-mercaptoethanol. After 24 h of culture, 50 &#x003bc;l of supernatants were transferred to culture wells containing 10<sup>4</sup> IL-2&#x02013; responsive CTLL-2 cells. During the final 4 h of a 24-h culture,  CTLL-2 cells were pulsed with 1 &#x003bc;Ci [<sup>3</sup>H]thymidine. Thymidine  incorporation was measured by scintillation spectrometry. The  concentration of peptide that caused 50% of maximum stimulation is referred to as SC<sub>50</sub>.</p><p><span class="head3">I-A<sup>g7</sup> Peptide-binding Assay. </span> Peptides were dissolved at 10 mM  in DMSO and diluted into 20% DMSO/PBS for assay. Indicator  I-A<sup>g7</sup> binding peptide, HEL 10&#x02013;23, was synthesized with a biotin  molecule and two spacer residues at the NH<sub>2</sub> terminus. Approximately 200 nM of this biotinylated HEL peptide and each test  peptide in seven concentrations ranging from 50 &#x003bc;M to 50 pM,  were coincubated with ~200 ng of I-A<sup>g7</sup> protein in U-bottomed  polypropylene 96-well plates (Costar Serocluster, Costar Corp.,  Cambridge, MA) in binding buffer at RT. The binding buffer  was 6.7 mM citric phosphate, pH 7.0, with 0.15 M NaCl, 2%  NP-40, 2 mM EDTA, and the protease inhibitors as used in the  lysis buffer. After a minimum of 24 h, each incubate was transferred to the corresponding well of an ELISA plate (Nunc Maxisorp, Nunc, Roskilde, Denmark) containing prebound OX-6  antibody (5 &#x003bc;g/ml overnight at 4&#x000b0;C, followed by washing). After  incubation at RT for at least 2 h, and washing, bound biotinylated peptide&#x02013;I-A<sup>g7</sup> complexes were detected colorimetrically at  405 nm after reaction with streptavidin&#x02013;alkaline phosphatase and  paranitrophenolphosphate. Competition binding curves were plotted  and the affinity of peptide for I-A<sup>g7</sup> was expressed as an inhibitory  concentration 50 (IC<sub>50</sub>), the concentration of peptide required to  inhibit the binding of bio-HEL 10&#x02013;23 by 50%.</p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id154430" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id343666" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Results and Discussion</a></div><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id353316" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id343937">Results and Discussion</div><div class="section-content"><p><span class="head4">I-A<sup>g7</sup> Purification and Binding Assay. </span> Approximately 2 mg  of protein, estimated by Coomassie blue binding (Bio Rad  Protein assay), was purified from 5 &#x000d7; 10<sup>10</sup> 4G4.7 cells. In  SDS-PAGE, the majority (&#x0003e;95%) of the protein was resolved as two bands of molecular weight ~33,000 and  ~28,000 that correspond to the &#x003b1; and &#x003b2; subunits, respectively, of mouse class II MHC molecules (data not shown).  The competition binding assay with purified I-A<sup>g7</sup> was sensitive and specific (Fig. <a href="articlerender.fcgi?artid=2196246&amp;rendertype=figure&amp;id=F1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">1</a>), and highly reproducible; in 15  separate assays the mean &#x000b1; SD of the IC<sub>50</sub> for competition  between biotinylated and unlabeled HEL 10&#x02013;23 was 295 &#x000b1;  72 nM. <div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="F1" name="F1"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=figure&amp;id=F1" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=2196246&amp;blobname=JEM.harrison1.gif" border="1" class="icon-reflink" alt="Figure 1" title="Figure 1"></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=2196246&amp;rendertype=figure&amp;id=F1" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Figure 1</strong></a><div class="figure-table-caption-in-article"><span>Examples of competition between biotinylated HEL peptide  (amino acids 10&#x02013;23) and unlabeled peptides for binding to purified I-A<sup>g7</sup>,  measured by ELISA (see Materials and Methods). Unlabeled HEL 10&#x02013;23  (&#x025a1;) was used as an internal</span><a class="side-caption" style="font-size: 100%;" href="articlerender.fcgi?artid=2196246&amp;rendertype=figure&amp;id=F1" onclick="startTarget(this, 'figure', 1024, 800)"> (more ...)</a></div></td></tr></table></div></div><div style="clear:both;"></div><p>Carrasco-Marin et al. (<a href="#B8" class="cite-reflink bibr">8</a>) were unable to demonstrate direct binding of HEL 11&#x02013;25 to purified I-A<sup>g7</sup> and proposed  that I-A<sup>g7</sup> was inherently unstable. We found that purified  I-A<sup>g7</sup> stored at &#x02212;70&#x000b0;C for more than 1 yr reproducibly  bound HEL 10&#x02013;23 with high affinity. Therefore, our results do not support their hypothesis that I-A<sup>g7</sup> is inherently  unstable, which they postulated would impair its ability to  bind and induce tolerance to autoreactive peptides.</p></p><p><span class="head4">Truncation Analysis of HEL 9&#x02013;27. </span> Peptides representing  sequential truncations of HEL 9&#x02013;27, from either the NH<sub>2</sub>  or COOH-terminus, were each assayed in parallel for  binding to I-A<sup>g7</sup> and for their ability to activate the 2D12.1  hybridoma. Inspection of these data (Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T1" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">1</a>) reveals that  the minimum T cell epitope is M12-R21, and the minimum binder is M12-Y20 or K13-R21. <div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="T1" name="T1"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T1" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="Table 1" title="Table 1"></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T1" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Table 1</strong></a><div class="figure-table-caption-in-article"><span>Truncation Analysis of I-A<sup>g7</sup>&#x02013;restricted HEL 9&#x02013;27 Epitope</span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head4">Effect of Selected Substitutions on Binding and Bioactivity of  HEL 12&#x02013;22. </span> Substitution of alanine (A) at each position  in HEL 12&#x02013;22 (Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T2" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">2</a>) had no significant effect on binding, with the sole exceptions of positions L17 and Y20.  Substitution at either of these two positions virtually abolished binding. On the other hand, while having no effect  on binding, substitutions by A at K13, R14, H15, G16,  and D18, and to a lesser extent at R21, abolished T cell activation. Removal of R21 (see Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T1" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">1</a>) abolished T cell  activation. Further substitutions of representative amino acids (D, K, P, Y, L, Q) at each position (Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T2" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">2</a>) revealed  varying levels of tolerance of specific residues/positions for  binding (see below) and generally confirmed the results of  the alanine substitutions on T cell activation. On the basis  of these results, we can deduce that most residues in the  minimal T cell epitope HEL 12&#x02013;21 have TCR contacts  and that two, L17 and Y20, are essential for binding to I-A<sup>g7</sup>  (Fig. <a href="articlerender.fcgi?artid=2196246&amp;rendertype=figure&amp;id=F2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)">2</a>).  <div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="T2" name="T2"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T2" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="Table 2" title="Table 2"></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T2" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Table 2</strong></a><div class="figure-table-caption-in-article"><span>Effect of Selected Amino Acid Substitutions on Binding and T Cell Activation of HEL 10&#x02013;22<sup>&#x0002a;</sup></span></div></td></tr></table></div></div><div style="clear:both;"></div><div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="F2" name="F2"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=figure&amp;id=F2" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=2196246&amp;blobname=JEM.harrison2.gif" border="1" class="icon-reflink" alt="Figure 2" title="Figure 2"></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=2196246&amp;rendertype=figure&amp;id=F2" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Figure 2</strong></a><div class="figure-table-caption-in-article"><span>Minimal T cell epitope, HEL 12(M)&#x02013;21(R), showing TCR  contact residues and L and Y primary anchors for binding to I-A<sup>97</sup> at relative positions 6 and 9, and positions 3 and 8 at which specific residues are  also not tolerated for binding.</span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head4">Anchor Residues for Peptide Binding. </span> The critical roles of  L17 and Y20 in the HEL epitope, as model anchor residues  for binding to I-A<sup>g7</sup>, was demonstrated with poly(A) peptides (Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T3" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">3</a>). The nonbinding poly(A) peptide, KAA  AAAAAA, was converted to a super binder simply by incorporating L and Y at the same relative positions as in the  HEL epitope. Either residue alone was not sufficient. Binding was reconstituted only when these two residues were  appropriately spaced and in the correct order. In addition,  this approach reveals the importance of the frame or context of the anchor residues. The LAAY sequence must be  flanked by at least two As, an absence of which at the  COOH terminus can be compensated for by at least three  As on the NH<sub>2</sub> terminus, but not vice versa. This suggests  that binding of these specific residues within the I-A<sup>g7</sup>  groove requires stabilization by hydrogen bonding from  nonspecific flanking residues, in particular at the NH<sub>2</sub> terminus. For the purpose of further analysis, the relative positions (p) of L and Y in the HEL epitope 12&#x02013;21 are designated p6 and p9. <div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="T3" name="T3"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T3" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="Table 3" title="Table 3"></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T3" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Table 3</strong></a><div class="figure-table-caption-in-article"><span>Binding to I-A<sup>g7</sup> of L- and Y-substituted Poly(A) Peptides</span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head4">Effect of Multiple Substitutions at p6 and p9. </span> In addition to  the selected substitutions at all positions (see Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T2" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">2</a>), we  investigated the effect on binding of all possible substitutions (except labile cysteine) at p6 or p9. A single residue  substitution was classified as well tolerated, weakly tolerated, or nontolerated according to a threshold on its IC<sub>50</sub>  value: well tolerated, &#x0003c;1,000 nM; weakly tolerated, 1,000&#x02013; 10,000 nM; nontolerated, <img src="corehtml/pmc/pmcents/ges.gif" border="0" alt="[gt-or-equal, slanted]" />10,000 nM. Although somewhat arbitrary, this classification corresponds to generally  accepted notions of good binders, moderate binders, and  weak to non-binders. The results, combined with those  from Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T2" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">2</a>, are presented in Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T4" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">4</a>. Optimally, p6 is a  large, hydrophobic residue (L, I, M, V), whereas p9 is aromatic and hydrophobic (Y, F) or positively charged (K, R).  Most amino acids are not well tolerated at these anchor positions. Additionally, specific amino acids are not tolerated  at other positions, namely F and E at p3 and W and Y at  p8. This information allowed us to propose and test minimum  rules for a motif for I-A<sup>g7</sup> binding peptides. These were that  a binder must have the following: (<em>a</em>) two well-tolerated residues or one well-tolerated and one weakly-tolerated residue  at anchor positions p6 and p9, (<em>b</em>) no nontolerated residues  at positions p3 and p8, and (<em>c</em>) at least two residues flanking  p6 and p9, or at least three residues NH<sub>2</sub>-terminal of p6. <div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="T4" name="T4"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T4" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="Table 4" title="Table 4"></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T4" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Table 4</strong></a><div class="figure-table-caption-in-article"><span>Effects of Amino Acid Substitutions on Binding of HEL 12&#x02013;22 to I-A<sup>g7</sup></span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head4">Motifs in Peptides Known or Deduced to Bind I-A<sup>g7</sup>. </span> Relatively few peptides containing sequences that might bind to  I-A<sup>g7</sup> have been reported in the literature. They include  peptides that stimulate I-A<sup>g7</sup>&#x02013;restricted T cells or T cell  hybridomas, compete for antigen presentation to T cell hybridomas, induce EAE in Biozzi AB/H mice, or have been  eluted from I-A<sup>g7</sup> (listed in Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T5" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">5</a>). It should be noted  that apart from the present study and that of CarrascoMarin et al. (<a href="#B8" class="cite-reflink bibr">8</a>), binding has not been determined by direct  peptide interaction with purified I-A<sup>g7</sup>, but either by elution  from I-A<sup>g7</sup>, competition with peptides that activate I-A<sup>g7</sup>&#x02013; bearing T cell hybridomas or induction of EAE. The motif  we have defined correctly identifies 27/30 (90%) of the  published sequences (Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T5" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">5</a>). Interestingly, we found that  one of these sequences, mouse serum albumin 560&#x02013;574, that  does not contain the motif, did not bind to I-A<sup>g7</sup> (data not  shown). <div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="T5" name="T5"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T5" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="Table 5" title="Table 5"></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T5" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Table 5</strong></a><div class="figure-table-caption-in-article"><span>Motif in Reported I-A<sup>g7</sup> Binding Peptides</span></div></td></tr></table></div></div><div style="clear:both;"></div><p>Two groups have suggested putative motifs for peptides  that bind to I-A<sup>g7</sup>. Reich et al. (<a href="#B7" class="cite-reflink bibr">7</a>) found that several peptides eluted from I-A<sup>g7</sup> had an acidic residue at the COOH  terminus. Their data also indicated that this residue was  separated by three from a basic residue. Whereas basic residues are major p9 anchors in our motif, an acidic residue at  the COOH terminus is not a uniform feature of other peptides deduced (Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T5" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">5</a>) or shown (Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T6" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">6</a>) to bind to I-A<sup>g7</sup>.  However, it is conceivable that in some cases, e.g., OVA  323&#x02013;339 (see Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T5" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">5</a>), a COOH-terminal acidic residue  could compensate for a nontolerated residue at p9. Amor et al.  (<a href="#B9" class="cite-reflink bibr">9</a>) described a possible motif shared by encephalitogenic  peptides in the Biozzi AB/H (I-A<sup>g7</sup>) mouse. It contained  hydrophobic (I or L), basic (K, R, or H), a small T cell  contact (A or G) and large hydrophobic (L or F) residues  within a 6&#x02013; to 7&#x02013;amino acid core. They studied the effect  of K substitutions on the immunogenicity of phospholipid  protein 56&#x02013;70 (see Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T5" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">5</a>), in which they had deduced a  core sequence, NVIHAFQ, necessary for the induction of  EAE. This sequence contains our motif I (p6) and F (p9).  K substitutions at I, H, A, or F completely abolished the  ability of the peptide to induce EAE. We would have predicted abolition of binding by the K substitution at I or A  and, by analogy with HEL (see Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T2" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">2</a>), a significant reduction in T cell activation by K substitution at H or F.  Thus, the features of this encephalitogenic motif are contained within the expanded and generalized motif we have  described. </p><div style="margin: 1em; margin-right: 2em;                                 border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="T6" name="T6"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T6" class="icon-reflink" onclick="startTarget(this, 'table', 1024, 800)"><img src="corehtml/pmc/pmcgifs/table-icon.gif" border="1" class="icon-reflink" alt="Table 6" title="Table 6"></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T6" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Table 6</strong></a><div class="figure-table-caption-in-article"><span>Overlapping Human Proinsulin Peptides Tested for  Binding to I-A<sup>g7</sup></span></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><span class="head4">Presence of Motif in Overlapping Peptides from Human Proinsulin. </span> We tested peptides overlapping by four residues and  spanning the entire sequence of human proinsulin for binding to I-A<sup>g7</sup>, and inspected them for presence of the binding motif (Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T6" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">6</a>). All six (100%) good binders contained  a motif. However, a motif was present in 4/13 (30%) weak  or non-binders. Clearly, the motif rules do not fully account for the effects of residue combinations or flanking sequences. Proinsulin 5&#x02013;19 has a well-tolerated V at p6 and a  weakly tolerated L at p9 yet did not bind, but when this  anchor pair moves towards the NH<sub>2</sub> terminus in the following 9&#x02013;23 sequence, the peptide becomes a binder. Proinsulin 45&#x02013;59 has a well-tolerated L at p6 and a weakly tolerated L at p9 and binds with high affinity, but when this  anchor pair moves towards the NH<sub>2</sub> terminus in the following 49&#x02013;63 sequence, the affinity of the peptide decreases. Human proinsulin 17&#x02013;31 has a weakly tolerated Y  at p6 and a well-tolerated K at p9, yet does not bind. Although this anchor pair is close to the COOH terminus,  this does not preclude other peptides, e.g., human proinsulin 65&#x02013;79, from binding with high affinity. However, human proinsulin 17&#x02013;31 has a positively charged p9/COOH  terminus, whereas the other binding peptides are generally  neutral or tend to be acidic. Reich et al. (<a href="#B7" class="cite-reflink bibr">7</a>) noted a bias towards acidic residues at the COOH termini of peptides  they eluted from I-A<sup>g7</sup>. When the anchor pair in this peptide moves towards the NH<sub>2</sub> terminus in the following 21&#x02013; 35 sequence with an acidic COOH terminus, the peptide  becomes a binder. Thus, in a small set of unbiased peptides,  the motif appears to have high sensitivity and some degree  of specificity. A similar degree of specificity was found for  an I-E<sup>k</sup> motif by correlating binding with the presence of  the motif in a panel of ~150 peptides (<a href="#B23" class="cite-reflink bibr">23</a>).<p>Although the core region length of class II MHC binding peptides is ~13 residues (<a href="#B24" class="cite-reflink bibr">24</a>), analysis of binding motifs  (<a href="#B25" class="cite-reflink bibr">25</a>) indicates that only nine residues within the core region  are essential for binding. The motif we describe conforms  with this requirement. It is simplistic in the sense that each  residue is assumed to contribute to binding independently  of other residues and, when located at a given position, to  contribute the same amount to binding even within different sequences. The rules that govern binding to class II  MHC molecules are more complex and will have to take  account of interactions between residues. Nevertheless, by  defining tolerated and nontolerated residues for binding at  key positions in HEL 12&#x02013;22, we appear to have unearthed  general rules that identify a large majority of known binders to I-A<sup>g7</sup>, and discriminate most non-binders.</p><p>The high sensitivity of the motif for reported I-A<sup>g7</sup> binders or T cell epitopes is remarkable, but the utility of the  motif will depend on its specificity, i.e., its absence in nonbinders. Specificity was 70% for the peptides in Table <a href="articlerender.fcgi?artid=2196246&amp;rendertype=table&amp;id=T6" class="fig-table-link " onclick="startTarget(this, 'table', 1024, 800)">6</a>,  but the database is small. Even if somewhat degenerate in  its present form, the motif should considerably narrow the  search for possible binders. The I-A<sup>g7</sup> binding assay we  have described is robust and will enable the database of  binders and non-binders to be enlarged progressively to  further validate the motif. Experiments to fine tune the  motif by using peptide libraries are in progress. Just as a  motif for human class II DR4 (*0401) binding peptides was  applied to scan candidate autoantigen proteins in rheumatoid arthritis for potential epitopes (<a href="#B26" class="cite-reflink bibr">26</a>), so also might the  motif for I-A<sup>g7</sup> binding be applied to identify potential autoepitopes for IDDM in NOD mice and CR-EAE in  Biozzi AB/H mice.</p></p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"> </td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="footnotes">Footnotes</div><div class="section-content"><div class="fm-footnote"><div class="p">L.C. Harrison and M.C. Honeyman were supported by the National Health and Medical Research Council  of Australia and a Diabetes Interdisciplinary Research Program grant from the Juvenile Diabetes Foundation  International. P. Augstein was supported by Deutscher Akademischer Austauschdienst, Bonn. Secretarial assistance was provided by Margaret Thompson.</div></div><div class="fm-footnote"><div class="p"><sup>1</sup><img src="corehtml/pmc/pmcents/x2009.gif" border="0" alt=" " /><em>Abbreviations used in this paper:</em> CR-EAE, chronic relapsing experimental  allergic encephalomyelitis; DOC, sodium deoxycholate; EAE, experimental allergic encephalomyelitis; GAD, glutamic acid decarboxylase;  HEL, hen egg white lysozyme; IDDM, insulin-dependent diabetes mellitus;  MOG, myelin oligodendrocyte glycoprotein; MSA, mouse serum albumin;  NOD, nonobese diabetic; OGP, octyl-&#x003b2;-<span class="small-caps">d</span>-glucopyranoside; p, position;  PEG, polyethylene glycol; PLP, proteolypid protein; RT, room temperature. </div></div></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id154430" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id343666" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id343937" class="sidefm-pmclink" style="text-transform: none;">Results and Discussion</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>References</a></div></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id353316">References</div><div class="section-content"><div class="back-matter-section"><div class="ref-cit-blk" id="B1"><div class="ref-label">1.</div><div class="ref-cit">Kikutani, H; Makino, S. The murine autoimmune diabetes model: NOD and related strains. <span><span class="ref-journal">Adv Immunol. </span>1992;<span class="ref-vol">51</span>:285–322.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0tIhOJIbRqh8QVen9bmM_4mRKMX80pgnfqDP715Y_&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/1323922">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B2"><div class="ref-label">2.</div><div class="ref-cit">Liu, GY; Baker, D; Fairchild, S; Figueroa, F; QuarteyPapafio, R; Tone, M; Healey, D; Cooke, A; Turk, JL; Wraith, DC. Complete characterization of the expressed immune response genes in Biozzi AB/H mice: structural and functional identity between AB/H and NOD A region molecules. <span><span class="ref-journal">Immunogenetics. </span>1993;<span class="ref-vol">37</span>:296–300.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0l_KnFhXaYfoZBT1Au4zZB42JE8P4NG0Nqz28Jk01&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8420838">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B3"><div class="ref-label">3.</div><div class="ref-cit">Acha-Orbea, H; McDevitt, HO. The first external domain of the nonobese diabetic mouse class II I-A &#x003b2; chain is unique. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>1987;<span class="ref-vol">84</span>:2435–2439.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0f_iMAQjWMqxJyduNYluuDrXLVdn1JYCy5L_76Qlt&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/2882518">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B4"><div class="ref-label">4.</div><div class="ref-cit">Tait, BD; Harrison, LC. Overview: the major histocompatibility complex and insulin-dependent diabetes mellitus. <span><span class="ref-journal">Baillieres Clin Endocrinol &#x00026; Metab. </span>1991;<span class="ref-vol">5</span>:211–228.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0jiMBUxFLwoY8Lfyt3LACDnBbwuLMEAKLdbl7SQ_-&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/1892463">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B5"><div class="ref-label">5.</div><div class="ref-cit">Rammensee, H-G. Chemistry of peptides associated with MHC class I and class II molecules. <span><span class="ref-journal">Curr Opin Immunol. </span>1995;<span class="ref-vol">7</span>:85–96.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0hql8z9KBRuRT72AkDgHXkwOfC9X1ErjhxpiQOkpW&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/7772286">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B6"><div class="ref-label">6.</div><div class="ref-cit">Sinigaglia, F., and J. Hammer. 1994. Defining rules for the  peptide&#x02013;MHC class II interaction. Curr. Opin. Immunol. 6: 52&#x02013;56.</div></div><div class="ref-cit-blk" id="B7"><div class="ref-label">7.</div><div class="ref-cit">Reich, E-P; von Grafenstein, H; Barlow, A; Swendon, KE; Williams, K; Janeway, CA., Jr Self peptides isolated from MHC glycoproteins of non-obese diabetic mice. <span><span class="ref-journal">J Immunol. </span>1994;<span class="ref-vol">152</span>:2279–2288.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0pg2MVT4jvEwawwT1tDj10u81jLUR4lnvzJTIskja&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8133041">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B8"><div class="ref-label">8.</div><div class="ref-cit">Carrasco-Marin, E; Shimizu, J; Kanagawa, O; Unanue, ER. The class II MHC I-A<sup>g7</sup>molecules from nonobese diabetic mice are poor peptide binders. <span><span class="ref-journal">J Immunol. </span>1996;<span class="ref-vol">156</span>:450–458.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0dSB3C0ek6Kk6X-Q7THiQABsvRSwuvK-Z0_2OvAyX&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8543793">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B9"><div class="ref-label">9.</div><div class="ref-cit">Amor, S., J.K. O'Neill, M.M. Morris, R.M. Smith, D.C.  Wraith, N. Groome, and D. Baker. Encephalitogenic epitopes of myelin basic protein, proteolipid protein, and myelin  oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi AB/H (H-2A<sup>g</sup>7) mice  share an amino acid motif. <em>J. Immunol.</em> 156:3000&#x02013;3008.</div></div><div class="ref-cit-blk" id="B10"><div class="ref-label">10.</div><div class="ref-cit">Kappler, J; White, J; Wegmann, D; Mustain, E; Marrack, P. Antigen presentation by la<sup>&#x0002b;</sup>B cell hybridomas to H-2-restricted T cell hybridomas. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>1982;<span class="ref-vol">79</span>:3604–3608.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0vEIMnGzTQaiJ4yU7bhe8OHvmCSITb6HP1a-IEQZ_&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/6980413">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B11"><div class="ref-label">11.</div><div class="ref-cit">O'Reilly, LA; Hutchings, PR; Crocker, PR; Simpson, E; Lund, T; Kioussis, D; Takei, F; Baird, J; Cooke, A. Characterization of pancreatic islet cell infiltrates in NOD mice: effect of cell transfer and transgene expression. <span><span class="ref-journal">Eur J  Immunol. </span>1991;<span class="ref-vol">21</span>:1171–1180.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0hSWJOUfA5eETvc6n70twjSEfzzeu5Cd9T1VoCQvZ&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/1674689">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B12"><div class="ref-label">12.</div><div class="ref-cit">Chosich, N; Harrison, LC. Suppression of diabetes mellitus in the non-obese diabetic (NOD) mouse by an  autoreactive (anti-T-A<sup>nod</sup>) islet-derived CD4&#x0002b; T cell line. <span><span class="ref-journal">Diabetologia. </span>1993;<span class="ref-vol">36</span>:716–721.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0ruCYZ6ieavRX9Kcz2SdcpPBibnSyEiNmJM9qBQHs&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8405738">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B13"><div class="ref-label">13.</div><div class="ref-cit">Adorini, L; Sette, A; Buus, S; Grey, HM; Darsley, M; Lehmann, PV; Doria, G; Nagy, ZA; Appella, E. Interaction of an immunodominant epitope with Ia molecules in T-cell activation. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>1988;<span class="ref-vol">85</span>:5181–5185.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0LmDqhaaZZIwTVipMs0HCdfatcK_D1Qd0UndWSAnN&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/2455895">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B14"><div class="ref-label">14.</div><div class="ref-cit">Hurtenbach, U; Lier, E; Adorini, L; Nagy, ZA. Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex&#x02013;blocking peptide. <span><span class="ref-journal">J Exp Med. </span>1993;<span class="ref-vol">177</span>:1499–1594.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0DGc4NayLvEIAy8EQP9FR0KTTRAWrfUcaNmmi-kCP&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8478620">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B15"><div class="ref-label">15.</div><div class="ref-cit">Deng, H; Apple, R; Clare-Salzler, M; Trembleau, S; Mathis, D; Adorini, L; Sercarz, E. Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease. <span><span class="ref-journal">J Exp Med. </span>1993;<span class="ref-vol">178</span>:1675–1680.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=02IYY09iHX_vQjdweJMLXFnLiPuIWsnlVADn6_kuQ&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8228814">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B16"><div class="ref-label">16.</div><div class="ref-cit">Chen, S-L; Whiteley, PJ; Freed, DC; Rothbard, JB; Peterson, LB; Wicker, LS. Responses of NOD congenic mice to a glutamic acid decarboxylase&#x02013;derived peptide. <span><span class="ref-journal">J Autoimmunity. </span>1994;<span class="ref-vol">7</span>:635–641.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0xAd02516lXa-EEtvrWos-DUYxaxo58-B3vKkfQPO&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/7840855">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B17"><div class="ref-label">17.</div><div class="ref-cit">Kaufman, D.L., M. Clare-Salzler, J. Tian, T. Forsthuber,  G.S.P. Ting, P. Robinson, M.A. Atkinson, E.E. Sercarz, A.J.  Tobin, and P.V. Lehmann. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. <em>Nature (Lond.).</em> 366:69&#x02013;72.</div></div><div class="ref-cit-blk" id="B18"><div class="ref-label">18.</div><div class="ref-cit">Smilek, DE; Lock, CB; McDevitt, HO. Antigen recognition and peptide-mediated immunotherapy in autoimmune disease. <span><span class="ref-journal">Immunol Rev. </span>1990;<span class="ref-vol">118</span>:37–71.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0psyJE24hPFSFrizvnO4sEyOagkgypaHyIneo-5BE&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/1706681">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B19"><div class="ref-label">19.</div><div class="ref-cit">Vaysburd, M; Lock, C; McDevitt, H. Prevention of insulin-dependent diabetes mellitis in nonobese diabetic mice by immunogenic but not by tolerated peptides. <span><span class="ref-journal">J Exp  Med. </span>1995;<span class="ref-vol">182</span>:897–902.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0TQpAkXF1HcQce1CChrnNJGnTCnDPZVGF694j4Qi1&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/7650494">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B20"><div class="ref-label">20.</div><div class="ref-cit">Daniel, D; Wegmann, DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9&#x02013;23). <span><span class="ref-journal">Proc Natl  Acad Sci USA. </span>1996;<span class="ref-vol">93</span>:956–960.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0levey1ecWf84WN2oweTrd6sCi8hdiMejJtno2Q7W&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8570667">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B21"><div class="ref-label">21.</div><div class="ref-cit">Ridgway, WM; Fasso, M; Lanctot, A; Garvey, C; Fathman, CG. Breaking self-tolerance in nonobese diabetic mice. <span><span class="ref-journal">J Exp Med. </span>1996;<span class="ref-vol">183</span>:1657–1662.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0faDgdHCnxem8eUhT5ttxctdxpi8Hc5B76uM0-5zw&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8666923">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B22"><div class="ref-label">22.</div><div class="ref-cit">Bernard, C.C.A., T.G. Johns, A. Slavin, M. Ichikawa, C.  Ewing, J. Liu, and J. Bettadapura. 1996. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple  sclerosis. <em>J. Mol. Med.</em> In press.</div></div><div class="ref-cit-blk" id="B23"><div class="ref-label">23.</div><div class="ref-cit">Leighton, J; Sette, A; Sidney, J; Appella, E; Ehrhardt, C; Fuchs, S; Adorini, L. Comparison of structural requirements for interaction on the same peptide with I-E<sup>k</sup> and  I-E<sup>d</sup>molecules in the activation of MHC class II&#x02013;restricted T cells. <span><span class="ref-journal">J Immunol. </span>1991;<span class="ref-vol">147</span>:198–204.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0DKp4hH1YiqXkh6Z3S2FN8itVHLTkctIxCgmwQkNc&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/1711074">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B24"><div class="ref-label">24.</div><div class="ref-cit">Jardetzky, TS; Brown, JB; Gorga, JC; Stern, LJ; Urban, RG; Strominger, JL; Wiley, DC. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II&#x02013;like conformation for bound peptides. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>1996;<span class="ref-vol">93</span>:734–738.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0XUaE5CccJkdeeAFN0eNm4ouwF00mVibB3oMfPQMb&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8570625">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B25"><div class="ref-label">25.</div><div class="ref-cit">Rammensee, HG; Friede, T; Stevanovic, S. MHC ligands and peptide motifs: first listing. <span><span class="ref-journal">Immunogenetics. </span>1995;<span class="ref-vol">41</span>:178–228.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0PkfK6PESzeKkkoap2kd4xLb40F7A0Xqd3IShN5lz&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/7890324">PubMed</a>]</span></div></div><div class="ref-cit-blk" id="B26"><div class="ref-label">26.</div><div class="ref-cit">Hammer, J; Gallazzi, F; Bono, E; Karr, RW; Guenot, J; Valsasnini, P; Nagy, ZA; Sinigaglia, F. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. <span><span class="ref-journal">J Exp Med. </span>1995;<span class="ref-vol">181</span>:1847–1855.</span>  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0rAaqk-VxWQ8-ApX5FGlHNqSP4n1Sm-2JrMKiqku3&amp;reftype=pubmed&amp;artid=2196246&amp;article-id=2196246&amp;iid=158993&amp;issue-id=158993&amp;jid=483&amp;journal-id=483&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/7722459">PubMed</a>]</span></div></div></div></div></td></tr><tr><td></td><td class="content-cell"><div class="footer-section"><hr><div class="sans90" style="margin: 0em 1em 1em; text-align: center;">Articles from <span class="acknowledgment-journal-title">The Journal of Experimental Medicine</span> are provided here courtesy of <br><b>The Rockefeller University Press</b></div>
      <div class="footer-link" id="fp-footer">
        <div>
          <a class="link" href="mailto:pubmedcentral@nih.gov">Write to PMC</a>
           | 
          <a class="link" href="./">PMC Home</a>
           | 
          <a class="link" href="http://www.ncbi.nlm.nih.gov/pubmed">PubMed</a>
        </div>
        <div>
          <a class="link" href="http://www.ncbi.nlm.nih.gov">NCBI</a>
           | 
          <a class="link" href="http://www.nlm.nih.gov">U.S. National Library of Medicine</a>
        </div>
        <div>
          <a class="link" href="http://www.nih.gov">NIH</a>
           | 
          <a class="link" href="http://www.hhs.gov/">Department of Health and Human Services</a>
        </div>
        <div>
          <a class="link" href="about/privacypolicy.html">Privacy Policy</a>
           | 
          <a class="link" href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Disclaimer</a>
           | 
          <a class="link" href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a>
        </div>
      </div>
    </div></td></tr></table></body></html><!--host:ipmc1-->

